Delirium in advanced cancer patients

Author:

Centeno Carlos1,Sanz Álvaro2,Bruera Eduardo3

Affiliation:

1. Centro Regional de Cuidados Paliativos y Tratamiento del Dolor, Hospital Los Montalvos, Salamanca

2. Servicio de Oncologóa, Hospital Clónico Universitario, Valladolid

3. Department of Palliative and Rehabilitation Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

Abstract

Delirium in advanced cancer is often poorly identified and inappropriately managed. It is one of the most common causes for admission to clinical institutions and is the most frequently cited psychiatric disorder in terminal cancer. Diagnosis of delirium is defined as a disturbance of consciousness and attention with a change in cognition and/or perception. In addition, it develops suddenly and follows a fluctuating course and it is related to other causes, such as cancer, metabolic disorders or the effects of drugs. Delirium occurs in 26% to 44% of cancer patients admitted to hospital or hospice. Of all advanced cancer patients, over 80% eventually experience delirium in their final days. In advanced cancer, delirium is a multifactorial syndrome where opioids factor in almost 60% of episodes. Delirium in such patients, excluding terminal delirium, may be reversible in 50% of cases. Providing adequate end-of-life care for a patient with delirium is the main challenge. The family needs advice and it is important to create a relaxing environment for the patient. The primary therapeutic approach is to identify the reversible causes of delirium. Some therapeutic strategies have been shown to be effective: reduction or withdrawal of the psychoactive medication, opioid rotation, and hydration. Haloperidol is the most frequently used drug, and new neuroleptics such as risperidone or olanzapine are being tested with good results. Methylphenidate has been used for hypoactive delirium.

Publisher

SAGE Publications

Subject

Anesthesiology and Pain Medicine,General Medicine

Cited by 167 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Psychiatric Co-morbidities and Complications of Cancer and Cancer Treatment;Massachusetts General Hospital Comprehensive Clinical Psychiatry;2025

2. Association between hospital palliative care team intervention volume and patient outcomes;International Journal of Clinical Oncology;2024-06-24

3. Dexmedetomidine in Palliative Care: A Versatile New Weapon Against Delirium and Pain—Systematic Review;Journal of Palliative Medicine;2024-05-21

4. Delirium pathophysiology in cancer: neurofilament light chain biomarker – narrative review;BMJ Supportive & Palliative Care;2024-01-30

5. Delirium and psychoses;Neuropsychological and Psychosocial Foundations of Neuro-Oncology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3